Gram-Positive Bacterial Infections Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Gram-Positive Bacterial Infections Market to 2027 - Global Analysis and Forecasts by Disease (Methicillin-Resistant Staphylococcus Aureus (MRSA), Pneumonia, Sepsis, Sinusitis, Skin Disorders and Other Diseases); Drug Type (Antibiotic, Antifungal and Others); Route of Administration (Enteral, Parenteral and Others); Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies and Other Distribution Channels) and Geography

Report Code: TIPRE00004059 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Gram-positive bacteria are recognized as the leading class of bacteria to cause infection in humans. These bacteria retain gram stain due to which are observed as violet purple colored stains under the microscope. Infections caused due to gram positive bacteria are acquired through various sources. They are known to cause infections such as, pneumonia, sepsis and MRSA, among others. Due to their highly infectious nature, treatment of gram positive infections has been an area of focus during the recent years.

MARKET DYNAMICS
The gram-positive bacterial infections market is anticipated to grow in the forecast, owing to increase in the cases of gram-positive bacterial infections and a significant rise in antibacterial resistance. In addition, government initiatives and funding for R&D activities is expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE
The "Global Gram-Positive Bacterial Infections Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of gram-positive bacterial infections market with detailed market segmentation by disease, drug type, route of administration, distribution channel and geography. The global gram-positive bacterial infections market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading gram-positive bacterial infections market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global gram-positive bacterial infections market is segmented on the basis of disease, drug type, route of administration, distribution channel. Based on disease, the market is segmented as Methicillin-Resistant Staphylococcus Aureus (MRSA), pneumonia, sepsis, sinusitis, skin disorders and other diseases. The gram-positive bacterial infections market is categorized based on drug type such as, antibiotic, antifungal and others. Based on route of administration, the market is classified as, enteral, parenteral and others. Similarly, the market is categorized as per distribution channel such as, hospital pharmacies, drug stores and retail pharmacies and other distribution channels.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global gram-positive bacterial infections market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The gram-positive bacterial infections market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting gram-positive bacterial infections market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the gram-positive bacterial infections market in these regions.

MARKET PLAYERS
The reports cover key developments in the gram-positive bacterial infections market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from gram-positive bacterial infections market are anticipated to lucrative growth opportunities in the future with the rising demand for gram-positive bacterial infections market in the global market. Below mentioned is the list of few companies engaged in the gram-positive bacterial infections market.

The report also includes the profiles of key gram-positive bacterial infections market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • ALLERGAN
  • AstraZeneca
  • Bayer AG
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • NovaBiotics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Theravance Biopharma
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Gram-positive Bacterial Infections Market - By Disease
1.3.2 Gram-positive Bacterial Infections Market - By Drug Type
1.3.3 Gram-positive Bacterial Infections Market - By Route of Administration
1.3.4 Gram-positive Bacterial Infections Market - By Distribution Channel
1.3.5 Gram-positive Bacterial Infections Market - By Region
1.3.5.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET - GLOBAL MARKET ANALYSIS
6.1. GRAM-POSITIVE BACTERIAL INFECTIONS - GLOBAL MARKET OVERVIEW
6.2. GRAM-POSITIVE BACTERIAL INFECTIONS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE
7.1. OVERVIEW
7.2. DISEASE MARKET FORECASTS AND ANALYSIS
7.3. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
7.3.1. Overview
7.3.2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Market Forecast and Analysis
7.4. PNEUMONIA
7.4.1. Overview
7.4.2. Pneumonia Market Forecast and Analysis
7.5. SEPSIS
7.5.1. Overview
7.5.2. Sepsis Market Forecast and Analysis
7.6. SINUSITIS
7.6.1. Overview
7.6.2. Sinusitis Market Forecast and Analysis
7.7. SKIN DISORDERS
7.7.1. Overview
7.7.2. Skin Disorders Market Forecast and Analysis
7.8. OTHER DISEASES
7.8.1. Overview
7.8.2. Other Diseases Market Forecast and Analysis
8. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
8.1. OVERVIEW
8.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
8.3. ANTIBIOTIC
8.3.1. Overview
8.3.2. Antibiotic Market Forecast and Analysis
8.4. ANTIFUNGAL
8.4.1. Overview
8.4.2. Antifungal Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ENTERAL
9.3.1. Overview
9.3.2. Enteral Market Forecast and Analysis
9.4. PARENTERAL
9.4.1. Overview
9.4.2. Parenteral Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
10.1. OVERVIEW
10.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
10.3. HOSPITAL PHARMACIES
10.3.1. Overview
10.3.2. Hospital Pharmacies Market Forecast and Analysis
10.4. DRUG STORES AND RETAIL PHARMACIES
10.4.1. Overview
10.4.2. Drug Stores and Retail Pharmacies Market Forecast and Analysis
10.5. OTHER DISTRIBUTION CHANNELS
10.5.1. Overview
10.5.2. Other Distribution Channels Market Forecast and Analysis
11. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Gram-positive Bacterial Infections Market Overview
11.1.2 North America Gram-positive Bacterial Infections Market Forecasts and Analysis
11.1.3 North America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Disease
11.1.4 North America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Drug Type
11.1.5 North America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Route of Administration
11.1.6 North America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Distribution Channel
11.1.7 North America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Countries
11.1.7.1 United States Gram-positive Bacterial Infections Market
11.1.7.1.1 United States Gram-positive Bacterial Infections Market by Disease
11.1.7.1.2 United States Gram-positive Bacterial Infections Market by Drug Type
11.1.7.1.3 United States Gram-positive Bacterial Infections Market by Route of Administration
11.1.7.1.4 United States Gram-positive Bacterial Infections Market by Distribution Channel
11.1.7.2 Canada Gram-positive Bacterial Infections Market
11.1.7.2.1 Canada Gram-positive Bacterial Infections Market by Disease
11.1.7.2.2 Canada Gram-positive Bacterial Infections Market by Drug Type
11.1.7.2.3 Canada Gram-positive Bacterial Infections Market by Route of Administration
11.1.7.2.4 Canada Gram-positive Bacterial Infections Market by Distribution Channel
11.1.7.3 Mexico Gram-positive Bacterial Infections Market
11.1.7.3.1 Mexico Gram-positive Bacterial Infections Market by Disease
11.1.7.3.2 Mexico Gram-positive Bacterial Infections Market by Drug Type
11.1.7.3.3 Mexico Gram-positive Bacterial Infections Market by Route of Administration
11.1.7.3.4 Mexico Gram-positive Bacterial Infections Market by Distribution Channel
11.2. EUROPE
11.2.1 Europe Gram-positive Bacterial Infections Market Overview
11.2.2 Europe Gram-positive Bacterial Infections Market Forecasts and Analysis
11.2.3 Europe Gram-positive Bacterial Infections Market Forecasts and Analysis - By Disease
11.2.4 Europe Gram-positive Bacterial Infections Market Forecasts and Analysis - By Drug Type
11.2.5 Europe Gram-positive Bacterial Infections Market Forecasts and Analysis - By Route of Administration
11.2.6 Europe Gram-positive Bacterial Infections Market Forecasts and Analysis - By Distribution Channel
11.2.7 Europe Gram-positive Bacterial Infections Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Gram-positive Bacterial Infections Market
11.2.7.1.1 Germany Gram-positive Bacterial Infections Market by Disease
11.2.7.1.2 Germany Gram-positive Bacterial Infections Market by Drug Type
11.2.7.1.3 Germany Gram-positive Bacterial Infections Market by Route of Administration
11.2.7.1.4 Germany Gram-positive Bacterial Infections Market by Distribution Channel
11.2.7.2 France Gram-positive Bacterial Infections Market
11.2.7.2.1 France Gram-positive Bacterial Infections Market by Disease
11.2.7.2.2 France Gram-positive Bacterial Infections Market by Drug Type
11.2.7.2.3 France Gram-positive Bacterial Infections Market by Route of Administration
11.2.7.2.4 France Gram-positive Bacterial Infections Market by Distribution Channel
11.2.7.3 Italy Gram-positive Bacterial Infections Market
11.2.7.3.1 Italy Gram-positive Bacterial Infections Market by Disease
11.2.7.3.2 Italy Gram-positive Bacterial Infections Market by Drug Type
11.2.7.3.3 Italy Gram-positive Bacterial Infections Market by Route of Administration
11.2.7.3.4 Italy Gram-positive Bacterial Infections Market by Distribution Channel
11.2.7.4 Spain Gram-positive Bacterial Infections Market
11.2.7.4.1 Spain Gram-positive Bacterial Infections Market by Disease
11.2.7.4.2 Spain Gram-positive Bacterial Infections Market by Drug Type
11.2.7.4.3 Spain Gram-positive Bacterial Infections Market by Route of Administration
11.2.7.4.4 Spain Gram-positive Bacterial Infections Market by Distribution Channel
11.2.7.5 United Kingdom Gram-positive Bacterial Infections Market
11.2.7.5.1 United Kingdom Gram-positive Bacterial Infections Market by Disease
11.2.7.5.2 United Kingdom Gram-positive Bacterial Infections Market by Drug Type
11.2.7.5.3 United Kingdom Gram-positive Bacterial Infections Market by Route of Administration
11.2.7.5.4 United Kingdom Gram-positive Bacterial Infections Market by Distribution Channel
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Gram-positive Bacterial Infections Market Overview
11.3.2 Asia-Pacific Gram-positive Bacterial Infections Market Forecasts and Analysis
11.3.3 Asia-Pacific Gram-positive Bacterial Infections Market Forecasts and Analysis - By Disease
11.3.4 Asia-Pacific Gram-positive Bacterial Infections Market Forecasts and Analysis - By Drug Type
11.3.5 Asia-Pacific Gram-positive Bacterial Infections Market Forecasts and Analysis - By Route of Administration
11.3.6 Asia-Pacific Gram-positive Bacterial Infections Market Forecasts and Analysis - By Distribution Channel
11.3.7 Asia-Pacific Gram-positive Bacterial Infections Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Gram-positive Bacterial Infections Market
11.3.7.1.1 Australia Gram-positive Bacterial Infections Market by Disease
11.3.7.1.2 Australia Gram-positive Bacterial Infections Market by Drug Type
11.3.7.1.3 Australia Gram-positive Bacterial Infections Market by Route of Administration
11.3.7.1.4 Australia Gram-positive Bacterial Infections Market by Distribution Channel
11.3.7.2 China Gram-positive Bacterial Infections Market
11.3.7.2.1 China Gram-positive Bacterial Infections Market by Disease
11.3.7.2.2 China Gram-positive Bacterial Infections Market by Drug Type
11.3.7.2.3 China Gram-positive Bacterial Infections Market by Route of Administration
11.3.7.2.4 China Gram-positive Bacterial Infections Market by Distribution Channel
11.3.7.3 India Gram-positive Bacterial Infections Market
11.3.7.3.1 India Gram-positive Bacterial Infections Market by Disease
11.3.7.3.2 India Gram-positive Bacterial Infections Market by Drug Type
11.3.7.3.3 India Gram-positive Bacterial Infections Market by Route of Administration
11.3.7.3.4 India Gram-positive Bacterial Infections Market by Distribution Channel
11.3.7.4 Japan Gram-positive Bacterial Infections Market
11.3.7.4.1 Japan Gram-positive Bacterial Infections Market by Disease
11.3.7.4.2 Japan Gram-positive Bacterial Infections Market by Drug Type
11.3.7.4.3 Japan Gram-positive Bacterial Infections Market by Route of Administration
11.3.7.4.4 Japan Gram-positive Bacterial Infections Market by Distribution Channel
11.3.7.5 South Korea Gram-positive Bacterial Infections Market
11.3.7.5.1 South Korea Gram-positive Bacterial Infections Market by Disease
11.3.7.5.2 South Korea Gram-positive Bacterial Infections Market by Drug Type
11.3.7.5.3 South Korea Gram-positive Bacterial Infections Market by Route of Administration
11.3.7.5.4 South Korea Gram-positive Bacterial Infections Market by Distribution Channel
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Gram-positive Bacterial Infections Market Overview
11.4.2 Middle East and Africa Gram-positive Bacterial Infections Market Forecasts and Analysis
11.4.3 Middle East and Africa Gram-positive Bacterial Infections Market Forecasts and Analysis - By Disease
11.4.4 Middle East and Africa Gram-positive Bacterial Infections Market Forecasts and Analysis - By Drug Type
11.4.5 Middle East and Africa Gram-positive Bacterial Infections Market Forecasts and Analysis - By Route of Administration
11.4.6 Middle East and Africa Gram-positive Bacterial Infections Market Forecasts and Analysis - By Distribution Channel
11.4.7 Middle East and Africa Gram-positive Bacterial Infections Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Gram-positive Bacterial Infections Market
11.4.7.1.1 South Africa Gram-positive Bacterial Infections Market by Disease
11.4.7.1.2 South Africa Gram-positive Bacterial Infections Market by Drug Type
11.4.7.1.3 South Africa Gram-positive Bacterial Infections Market by Route of Administration
11.4.7.1.4 South Africa Gram-positive Bacterial Infections Market by Distribution Channel
11.4.7.2 Saudi Arabia Gram-positive Bacterial Infections Market
11.4.7.2.1 Saudi Arabia Gram-positive Bacterial Infections Market by Disease
11.4.7.2.2 Saudi Arabia Gram-positive Bacterial Infections Market by Drug Type
11.4.7.2.3 Saudi Arabia Gram-positive Bacterial Infections Market by Route of Administration
11.4.7.2.4 Saudi Arabia Gram-positive Bacterial Infections Market by Distribution Channel
11.4.7.3 U.A.E Gram-positive Bacterial Infections Market
11.4.7.3.1 U.A.E Gram-positive Bacterial Infections Market by Disease
11.4.7.3.2 U.A.E Gram-positive Bacterial Infections Market by Drug Type
11.4.7.3.3 U.A.E Gram-positive Bacterial Infections Market by Route of Administration
11.4.7.3.4 U.A.E Gram-positive Bacterial Infections Market by Distribution Channel
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Gram-positive Bacterial Infections Market Overview
11.5.2 South and Central America Gram-positive Bacterial Infections Market Forecasts and Analysis
11.5.3 South and Central America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Disease
11.5.4 South and Central America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Drug Type
11.5.5 South and Central America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Route of Administration
11.5.6 South and Central America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Distribution Channel
11.5.7 South and Central America Gram-positive Bacterial Infections Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Gram-positive Bacterial Infections Market
11.5.7.1.1 Brazil Gram-positive Bacterial Infections Market by Disease
11.5.7.1.2 Brazil Gram-positive Bacterial Infections Market by Drug Type
11.5.7.1.3 Brazil Gram-positive Bacterial Infections Market by Route of Administration
11.5.7.1.4 Brazil Gram-positive Bacterial Infections Market by Distribution Channel
11.5.7.2 Argentina Gram-positive Bacterial Infections Market
11.5.7.2.1 Argentina Gram-positive Bacterial Infections Market by Disease
11.5.7.2.2 Argentina Gram-positive Bacterial Infections Market by Drug Type
11.5.7.2.3 Argentina Gram-positive Bacterial Infections Market by Route of Administration
11.5.7.2.4 Argentina Gram-positive Bacterial Infections Market by Distribution Channel
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. GRAM-POSITIVE BACTERIAL INFECTIONS MARKET, KEY COMPANY PROFILES
13.1. ALLERGAN
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ASTRAZENECA
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BAYER AG
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE PLC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. MERCK & CO., INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. NOVABIOTICS LTD
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. NOVARTIS AG
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PFIZER INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. SANOFI
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERAVANCE BIOPHARMA
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. ALLERGAN
2. AstraZeneca
3. Bayer AG
4. GlaxoSmithKline plc.
5. Merck & Co., Inc.
6. NovaBiotics Ltd
7. Novartis AG
8. Pfizer Inc.
9. Sanofi
10. Theravance Biopharma